Lymphangioleiomyomatosis and TSC2-/- cells

Lymphatic Research and Biology

Volumn 8, Issue 1, 2010, Pages 59-69

  Darling, Thomas N ^a   Pacheco Rodriguez, Gustavo ^b   Gorio, Alfredo ^c,d   Lesma, Elena ^c   Walker, Cheryl ^e   Moss, Joel ^b  

^a Uniformed Services University of the Health Sciences   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; TUBERIN;

ANGIOMYOLIPOMA; CELL DIFFERENTIATION; CELL INTERACTION; ENZYME ACTIVATION; EXON; GENE EXPRESSION; GENE MUTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; LYMPHANGIOLEIOMYOMATOSIS; METASTASIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SKIN TUMOR; SMOOTH MUSCLE FIBER; UTERUS MYOMA;

ANIMALS; DISEASE MODELS, ANIMAL; HOMOZYGOTE; HUMANS; LYMPHANGIOLEIOMYOMATOSIS; MICE; MICE, KNOCKOUT; RATS; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 77949817814     PISSN: 15396851     EISSN: None     Source Type: Journal    
DOI: 10.1089/lrb.2009.0031     Document Type: Review

References (112)

1. Taveira-Da Silva AM, Steagall WK, Moss J. Lymphangioleiomyomatosis. Cancer Control 2006;13:276-285.
2. Juvet SC, McCormack FX, Kwiatkowski DJ, Downey GP. Molecular pathogenesis of lymphangioleiomyomatosis: Lessons learned from orphans. Am J Respir Cell Mol Biol 2007;36:398-408.
3. Zhe X, Schuger L. Combined smooth muscle and melanocytic differentiation in lymphangioleiomyomatosis. J Histochem Cytochem 2004;52:1537-1542.
4. Martignoni G, Pea M, Reghellin D, Zamboni G, Bonetti F. PEComas: The past, the present and the future. Virchows Arch 2008;452:119-132.
5. Folpe AL, Kwiatkowski DJ. Perivascular epithelioid cell neoplasms: Pathology and pathogenesis.Hum Pathol 2010;41:1-5.
6. Matsui K, Riemenschneider WK, Hilbert SL, et al. Hyperplasia of type II pneumocytes in pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med 2000;124:1642-1648.
7. Bohinski RJ, Di Lauro R, Whitsett JA. The lung-specific surfactant protein B gene promoter is a target for thyroid transcription factor 1 and hepatocyte nuclear factor 3, indicating common factors for organ-specific gene expression along the foregut axis. Mol Cell Biol 1994;14:5671-5681.
8. Margana RK, Boggaram V. Functional analysis of surfactant protein B (SP-B) promoter. Sp1, Sp3, TTF-1, and HNF-3alpha transcription factors are necessary for lung cell-specific activation of SP-B gene transcription. J Biol Chem 1997;272: 3083-3090.
9. Kumasaka T, Seyama K, Mitani K, et al. Lymphangiogenesismediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. Am J Surg Pathol 2005;29:1356-1366.
10. Valencia JC, Pacheco-Rodriguez G, Carmona AK, et al. Tissue-specific renin-angiotensin system in pulmonary lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 2006;35: 40-47.
11. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2000;97:6085-6090.
12. Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, Henske EP. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: Chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 1998;62:810-815.
13. Astrinidis A, Khare L, Carsillo T, et al. Mutational analysis of the tuberous sclerosis gene TSC2 in patients with pulmonary lymphangioleiomyomatosis. J Med Genet 2000;37: 55-57.
14. Pacheco-Rodriguez G, Steagall WK, Crooks DM, et al. TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis. Cancer Res 2007;67:10573-10581.
15. Goncharova EA, Goncharov DA, Eszterhas A, et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem 2002;277:30958-30967.
16. Karbowniczek M, Spittle CS, Morrison T, Wu H, Henske EP. mTOR is activated in the majority of malignant melanomas. J Invest Dermatol 2008;128:980-987.
17. Jastrzebski K, Hannan KM, Tchoubrieva EB, Hannan RD, Pearson RB. Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth Factors 2007;25:209-226.
18. Peterson TR, Laplante M, Thoreen CC, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009;137: 873-886.
19. Lesma E, Sirchia SM, Ancona S, et al. The methylation of the TSC2 promoter underlies the abnormal growth of TSC2 angiomyolipoma-derived smooth muscle cells. Am J Pathol 2009;174:2150-2159.
20. Valencia JC, Matsui K, Bondy C, et al. Distribution and mRNA expression of insulin-like growth factor system in pulmonarylymphangioleiomyomatosis. J InvestigMed 2001; 49:421-433.
21. El-Hashemite N, Zhang H, Walker V, Hoffmeister KM, Kwiatkowski DJ. Perturbed IFN-gamma-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of rapamycin-IFN-gamma treatment. Cancer Res 2004;64:3436-3443.
22. Goncharova EA, Goncharov DA, Chisolm A, et al. Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation. Mol Pharmacol 2008;73:778-788.
23. Zhe X, Yang Y, Schuger L. Imbalanced plasminogen system in lymphangioleiomyomatosis: Potential role of serum response factor. Am J Respir Cell Mol Biol 2005;32:28-34.
24. Black JL, Ge Q, Boustany S, et al. In vitro studies of lymphangioleiomyomatosis. Eur Respir J 2005;26:569-576.
25. Goncharova EA, Goncharov DA, Lim PN, Noonan D, Krymskaya VP. Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 2006;34:473-480.
26. Colley MH, Geppert E, Franklin WA. Immunohistochemical detection of steroid receptors in a case of pulmonary lymphangioleiomyomatosis. Am J Surg Pathol 1989;13:803-807.
27. Berger U, Khaghani A, Pomerance A, Yacoub MH, Coombes RC. Pulmonary lymphangioleiomyomatosis and steroid receptors. An immunocytochemical study.Am J Clin Pathol 1990;93:609-614.
28. Ohori NP, Yousem SA, Sonmez-Alpan E, Colby TV. Estrogen and progesterone receptors in lymphangioleiomyomatosis, epithelioid hemangioendothelioma, and sclerosing hemangioma of the lung. Am J Clin Pathol 1991;96:529-535
29. Matsui K, Takeda K, Yu ZX, et al. Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy. An immunohistochemical study. Am J Respir Crit Care Med 2000;161:1002-1009.
30. Yu JJ, Robb VA, Morrison TA, et al. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci USA 2009;106:2635-2640.
31. El-Hashemite N, Walker V, Kwiatkowski DJ. Estrogen enhances whereas tamoxifen retards development of Tsc mouse liver hemangioma: A tumor related to renal angiomyolipoma and pulmonary lymphangioleiomyomatosis. Cancer Res 2005;65:2474-2481.
32. Glassberg MK, Elliot SJ, Fritz J, et al. Activation of the estrogen receptor contributes to the progression of pulmonary lymphangioleiomyomatosis via matrix metalloproteinaseinduced cell invasiveness. J Clin Endocrinol Metab 2008;93: 1625-1633.
33. Boehler A, Speich R, Russi EW, Weder W. Lung transplantation for lymphangioleiomyomatosis. N Engl J Med 1996;335:1275-1280.
34. Nine JS, Yousem SA, Paradis IL, Keenan R, Griffith BP. Lymphangioleiomyomatosis: Recurrence after lung transplantation. J Heart Lung Transplant 1994;13:714-719.
35. Bittmann I, Dose TB, Muller C, Dienemann H, Vogelmeier C, Lohrs U. Lymphangioleiomyomatosis: Recurrence after single lung transplantation. Hum Pathol 1997;28:1420-1423.
36. Bittmann I, Rolf B, Amann G, Lohrs U. Recurrence of lymphangioleiomyomatosis after single lung transplantation: New insights into pathogenesis. Hum Pathol 2003;34:95-98.
37. O'Brien JD, Lium JH, Parosa JF, Deyoung BR, Wick MR, Trulock EP. Lymphangiomyomatosis recurrence in the allograft after single-lung transplantation. Am J Respir Crit Care Med 1995;151:2033-2036.
38. Crooks DM, Pacheco-Rodriguez G, DeCastro RM, et al. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2004;101:17462-17467.
39. Goncharova E, Goncharov D, Noonan D, Krymskaya VP. TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase. J Cell Biol 2004;167:1171-1182.
40. Pacheco-Rodriguez G, Kumaki F, Steagall WK, et al. Chemokine-enhanced chemotaxis of lymphangioleiomyomatosis cells with mutations in the tumor suppressor TSC2 gene. J Immunol 2009;182:1270-1277.
41. Eble JN. Angiomyolipoma of kidney. Semin Diagn Pathol 1998;15:21-40.
42. Henske EP, Ao X, Short MP, et al. Frequent progesterone receptor immunoreactivity in tuberous sclerosis-associated renal angiomyolipomas. Mod Pathol 1998;11:665-668.
43. Logginidou H, Ao X, Russo I, Henske EP. Frequent estrogen and progesterone receptor immunoreactivity in renal angiomyolipomas from women with pulmonary lymphangioleiomyomatosis. Chest 2000;117:25-30.
44. Karbowniczek M, Astrinidis A, Balsara BR, et al. Recurrent lymphangiomyomatosis after transplantation: Genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med 2003;167:976-982.
45. Maruyama H, Seyama K, Sobajima J, et al. Multifocal micronodular pneumocyte hyperplasia and lymphangioleiomyomatosis in tuberous sclerosis with a TSC2 gene. Mod Pathol 2001;14:609-614.
46. Henske EP, Neumann HP, Scheithauer BW, Herbst EW, Short MP, Kwiatkowski DJ. Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas. Genes Chromosomes Cancer 1995;13:295-298.
47. Niida Y, Stemmer-Rachamimov AO, LogripM, et al. Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am J Hum Genet 2001;69:493-503.
48. Martignoni G, Pea M, Bonetti F, et al. Carcinomalike monotypic epithelioid angiomyolipoma in patients without evidence of tuberous sclerosis: A clinicopathologic and genetic study. Am J Surg Pathol 1998;22:663-672.
49. Neumann HP, Schwarzkopf G, Henske EP. Renal angiomyolipomas, cysts, and cancer in tuberous sclerosis complex. Semin Pediatr Neurol 1998;5:269-275.
50. Karbowniczek M, Yu J, Henske EP. Renal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplastic and non-neoplastic vascular structures. Am J Pathol 2003;162:491-500.
51. Arbiser JL, Yeung R, Weiss SW, et al. The generation and characterization of a cell line derived from a sporadic renal angiomyolipoma: Use of telomerase to obtain stable populations of cells from benign neoplasms. Am J Pathol 2001; 159:483-491.
52. Yu J, Astrinidis A, Howard S, Henske EP. Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. Am J Physiol Lung Cell Mol Physiol 2004;286:L694-700.
53. Howe SR, Gottardis MM, Everitt JI, Walker C. Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo. Endocrinology 1995;136:4996-5003.
54. Kenerson HL, Aicher LD, True LD, Yeung RS. Activated mammalian target of rapamycin pathwayin the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 2002; 62:5645-5650.
55. Robb VA, Astrinidis A, Henske EP. Frequent [corrected] hyperphosphorylation of ribosomal protein S6 [corrected] in lymphangioleiomyomatosis-associated angiomyolipomas. Mod Pathol 2006;19:839-846.
56. Lesma E, Grande V, Carelli S, et al. Isolation and growth of smooth muscle-like cells derived from tuberous sclerosis complex-2 human renal angiomyolipoma: epidermal growth factor is the required growth factor. Am J Pathol 2005;167: 1093-1103.
57. Chan JA, Zhang H, Roberts PS, et al. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: Biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol 2004;63:1236-1242.
58. Henske EP, Scheithauer BW, Short MP, et al. Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet 1996;59:400-406.
59. Carelli S, Lesma E, Paratore S, et al. Survivin expression in tuberous sclerosis complex cells. Mol Med 2007;13: 166-177.
60. Lesma E, Grande V, Ancona S, Carelli S, Di Giulio AM, Gorio A. Anti-EGFR antibody efficiently and specifically inhibits human TSC2-=-smooth muscle cell proliferation. Possible treatment options for TSC and LAM. PLoS ONE 2008;3:e3558.
61. Vokes EE, Chu E. Anti-EGFR therapies: Clinical experience in colorectal, lung, and head and neck cancers. Oncology (Williston Park) 2006;20:15-25.
62. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008;358:140-151.
63. Pollizzi K, Malinowska-Kolodziej I, Stumm M, Lane H, Kwiatkowski D. Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis. Mol Cancer 2009;8:38.
64. Jozwiak S, Schwartz RA, Janniger CK, Michalowicz R, Chmielik J. Skin lesions in children with tuberous sclerosis complex: their prevalence, natural course, and diagnostic significance. Int J Dermatol 1998;37:911-917.
65. Nickel WR, Reed WB. Tuberous sclerosis. Special reference to the microscopic alterations in the cutaneous hamartomas. Arch Dermatol 1962;85:209-226.
66. Reed RJ, Ackerman AB. Pathology of the adventitial dermis. Anatomic observations and biologic speculations. Hum Pathol 1973;4:207-217.
67. Sanchez NP, Wick MR, Perry HO. Adenoma sebaceum of Pringle: A clinicopathologic review, with a discussion of related pathologic entities. J Cutan Pathol 1981;8:395-403.
68. Arbiser JL, Brat D, Hunter S, et al. Tuberous sclerosisassociated lesions of the kidney, brain, and skin are angiogenic neoplasms. J Am Acad Dermatol 2002;46:376-380.
69. Glasgow CG, Taveira-Dasilva AM, Darling TN, Moss J. Lymphatic involvement in lymphangioleiomyomatosis. Ann NY Acad Sci 2008;1131:206-214.
70. Li S, Takeuchi F, Wang JA, et al. Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas. Proc Natl Acad Sci USA 2008;105:3539-3544.
71. Nguyen-Vu PA, Fackler I, Rust A, et al. Loss of tuberin, the tuberous-sclerosis-complex-2 gene product is associated with angiogenesis. J Cutan Pathol 2001;28:470-475.
72. Fackler I, DeClue JE, Rust H, et al. Loss of expression of tuberin and hamartin in tuberous sclerosis complexassociated but not in sporadic angiofibromas. J Cutan Pathol 2003;30:174-177.
73. Sepp T, Yates JR, Green AJ. Loss of heterozygosity in tuberous sclerosis hamartomas. J Med Genet 1996;33:962-964.
74. Green AJ, Sepp T, Yates JR. Clonality of tuberous sclerosis harmatomas shown by non-random X-chromosome inactivation. Hum Genet 1996;97:240-243.
75. Au KS, Hebert AA, Roach ES, Northrup H. Complete inactivation of the TSC2 gene leads to formation of hamartomas. Am J Hum Genet 1999;65:1790-1795.
76. Wataya-Kaneda M, Kaneda Y, Hino O, et al. Cells derived from tuberous sclerosis show a prolonged S phase of the cell cycle and increased apoptosis. Arch Dermatol Res 2001; 293:460-469.
77. Li S, Wang J-a, Pacheco-Rodriguez G, Moss J, Darling. T. Rapamycin inhibits proliferation of cells from TSC skin tumors. AACR Meeting Abstracts 2007;2007:4066.
78. Kato M, Katsumoto T, Ohno K, Kato S, Herz F, Takeshita K. Expression of glial fibrillary acidic protein (GFAP) by cultured angiofibroma stroma cells from patients with tuberous sclerosis. Neuropathol Appl Neurobiol 1992;18: 559-565.
79. Li S, Takeuchi F, Wang JA, et al. MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development. J Exp Med 2005;202:617-624.
80. Toyoshima M, Ohno K, Katsumoto T, Maki H, Takeshita K. Cellular senescence of angiofibroma stroma cells from patients with tuberous sclerosis. Brain Dev 1999;21:184-191.
81. Rosner M, Freilinger A, Hengstschlager M. The tuberous sclerosis genes and regulation of the cyclin-dependent kinase inhibitor p27. Mutat Res 2006;613:10-16.
82. Gan B, Sahin E, Jiang S, et al. mTORC1-dependent and -independent regulation of stemcell renewal, differentiation, and mobilization. Proc Natl Acad Sci USA 2008;105:19384-19389.
83. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG, Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003;4:147-158.
84. El-Hashemite N, Walker V, Zhang H, Kwiatkowski DJ. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res 2003;63:5173-5177.
85. Govindarajan B, Brat DJ, Csete M, et al. Transgenic expression of dominant negative tuberin through a strong constitutive promoter results in a tissue-specific tuberous sclerosis phenotype in the skin and brain. J Biol Chem 2005;280:5870-5874.
86. Onda H, Lueck A, Marks PW, Warren HB, Kwiatkowski DJ. Tsc2(+=-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J Clin Invest 1999;104:687-695.
87. Kwiatkowski DJ, Zhang H, Bandura JL, et al. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet 2002;11:525-534.
88. Kobayashi M, Irino T, Sweldens W. Multiscale computing. Proc Natl Acad Sci USA 2001;98:12344-12345.
89. Kobayashi T, Minowa O, Kuno J, Mitani H, Hino O, Noda T. Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res 1999;59:1206-1211.
90. Zhang H, Cicchetti G, Onda H, et al. Loss of Tsc1=Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest 2003;112:1223-1233.
91. Pollizzi K, Malinowska-Kolodziej I, Doughty C, et al. A hypomorphic allele of Tsc2 highlights the role of TSC1=TSC2 in signaling to AKT and models mild human TSC2 alleles. Hum Mol Genet 2009;18:2378-2387.
92. Onda H, Crino PB, Zhang H, et al. Tsc2 null murine neuroepithelial cells are a model for human tuber giant cells, and show activation of an mTOR pathway. Mol Cell Neurosci 2002;21:561-574.
93. Harrington LS, Findlay GM, Gray A, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004;166:213-223.
94. Zhang H, Bajraszewski N, Wu E, et al. PDGFRs are critical for PI3K=Akt activation and negatively regulated by mTOR. J Clin Invest 2007;117:730-738.
95. Huang J, Dibble CC, Matsuzaki M, Manning BD. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol 2008;28:4104-4115.
96. Yeung RS, Xiao GH, Jin F, Lee WC, Testa JR, Knudson AG. Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene. Proc Natl Acad Sci USA 1994;91:11413-11416.
97. Kobayashi T, Hirayama Y, Kobayashi E, Kubo Y, Hino O. A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer. Nat Genet 1995;9:70-74.
98. Walker C, Goldsworthy TL, Wolf DC, Everitt J. Predisposition to renal cell carcinoma due to alteration of a cancer susceptibility gene. Science 1992;255:1693-1695.
99. Hino O, Klein-Szanto AJ, Freed JJ, et al. Spontaneous and radiation-induced renal tumors in the Eker rat model of dominantly inherited cancer. Proc Natl Acad Sci USA 1993; 90:327-331.
100. Everitt JI, Wolf DC, Howe SR, Goldsworthy TL, Walker CL. Rodent model of reproductive tract leiomyomata. Clinical and pathological features. Am J Pathol 1995;146: 1556-1567.
101. Binhazim AA, Coghlan LG, Walker C. Spontaneous hemangiosarcoma in the tail of a Long-Evans rat carrying the Eker mutation. Lab Anim Sci 1994;44:191-194.
102. Yeung RS, Xiao GH, Everitt JI, Jin F, Walker CL. Allelic loss at the tuberous sclerosis 2 locus in spontaneous tumors in the Eker rat. Mol Carcinog 1995;14:28-36.
103. Wenzel HJ, Patel LS, Robbins CA, Emmi A, Yeung RS, Schwartzkroin PA. Morphology of cerebral lesions in the Eker rat model of tuberous sclerosis. Acta Neuropathol 2004;108:97-108.
104. Kubo Y, Mitani H, Hino O. Allelic loss at the predisposing gene locus in spontaneous and chemically induced renal cell carcinomas in the Eker rat. Cancer Res 1994;54:2633-2635.
105. Kleymenova E, Ibraghimov-Beskrovnaya O, Kugoh H, et al. Tuberin-dependent membrane localization of polycystin-1. A functional link between polycystic kidney disease and the TSC2 tumor suppressor gene. Mol Cell 2001;7:823-832.
106. Soucek T, Yeung RS, Hengstschlager M. Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. Proc Natl Acad Sci USA 1998;95:15653-15658.
107. Howe SR, Gottardis MM, Everitt JI, Goldsworthy TL, Wolf DC, Walker C. Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumorderived cell lines. Am J Pathol 1995;146:1568-1579.
108. Crabtree JS, Jelinsky SA, Harris HA, et al. Comparison of human and rat uterine leiomyomata: Identification of a dysregulated mammalian target of rapamycin pathway. Cancer Res 2009;69:6171-6178.
109. Howe SR, Gottardis MM, Everitt JI, Walker C. Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo. Endocrinology 1995;136:4996-5003.
110. Hodges LC, Houston KD, Hunter DS, et al. Transdominant suppression of estrogen receptor signaling by progesterone receptor ligands in uterine leiomyoma cells. Mol Cell Endocrinol 2002;196:11-20.
111. Astrinidis A, Cash TP, Hunter DS, Walker CL, Chernoff J, Henske EP. Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration. Oncogene 2002;21:8470-8476.
112. Lee L, Sudentas P, Donohue B, et al. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer 2004.